These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32758460)

  • 21. [Research evolutions in immuno-oncology and their impact on the management of patients treated with immunotherapy].
    Caux C
    Bull Cancer; 2020 Jan; 107(1):6-9. PubMed ID: 31954504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational medicine promising personalized therapy in oncology.
    Zeng YX; Zhang XS; Liu Q
    Front Med China; 2010 Dec; 4(4):351-5. PubMed ID: 21107749
    [No Abstract]   [Full Text] [Related]  

  • 23. Immuno-oncology for surgeons.
    Lee SL; Al-Shamkhani A; Mirnezami A
    Br J Surg; 2019 Sep; 106(10):1273-1282. PubMed ID: 31318438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
    Maio M; Coukos G; Ferrone S; Fox BA; Fridman WH; Garcia PL; Lahn M; Provendier O; Russo V; Rüttinger D; Shalabi A; Trajanoski Z; Viallet J; Wolchok JD; Ibrahim R
    Cancer Immunol Immunother; 2019 Jan; 68(1):1-9. PubMed ID: 30564889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
    Seiden MV; Neubauer M; Verrilli D
    Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP69-SP77. PubMed ID: 28298130
    [No Abstract]   [Full Text] [Related]  

  • 26. [Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer].
    Bay JO; André T; Caux C; Evrard S; Gonçalves A; L'Allemain G; Magné N; Orbach D; Penel N; Rodrigues M; Thariat J; Thiery-Vuillemin A; Wislez M;
    Bull Cancer; 2019 Jan; 106(1):12-23. PubMed ID: 30612698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AACR Cancer Progress Report 2016.
    Davidson NE; Armstrong SA; Coussens LM; Cruz-Correa MR; DeBerardinis RJ; Doroshow JH; Foti M; Hwu P; Kensler TW; Morrow M; Mulligan CG; Pao W; Platz EA; Smith TJ; Willman CL
    Clin Cancer Res; 2016 Oct; 22 Suppl 19():S1-S137. PubMed ID: 27697776
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.
    Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN
    Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Federal task force seeks standards for immunotherapy biomarker studies.
    Finkelstein JB
    J Natl Cancer Inst; 2009 May; 101(10):704-6. PubMed ID: 19436032
    [No Abstract]   [Full Text] [Related]  

  • 30. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
    Kaplon H; Dieu-Nosjean MC
    Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of neuro-oncology.
    Piepmeier JM
    Acta Neurochir (Wien); 2009 Nov; 151(11):1343-8. PubMed ID: 19639245
    [No Abstract]   [Full Text] [Related]  

  • 32. The evolution of interventional oncology in the 21st century.
    Helmberger T
    Br J Radiol; 2020 Sep; 93(1113):20200112. PubMed ID: 32706978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future shock: embracing disruption in the immunotherapy revolution.
    Alvarnas J
    Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP34. PubMed ID: 29689140
    [No Abstract]   [Full Text] [Related]  

  • 34. [New frontiers in the fight against cancer].
    Chiossone L; Vivier E
    Biol Aujourdhui; 2018; 212(3-4):61-67. PubMed ID: 30973133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2020 ASCO Virtual Annual Meeting.
    Collingridge D
    Lancet Oncol; 2020 Jul; 21(7):885-886. PubMed ID: 32511985
    [No Abstract]   [Full Text] [Related]  

  • 36. [New immunological concepts in oncology].
    Versicherungsmedizin; 2013 Sep; 65(3):156-7. PubMed ID: 24137899
    [No Abstract]   [Full Text] [Related]  

  • 37. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology.
    Bonaca MP; Olenchock BA; Salem JE; Wiviott SD; Ederhy S; Cohen A; Stewart GC; Choueiri TK; Di Carli M; Allenbach Y; Kumbhani DJ; Heinzerling L; Amiri-Kordestani L; Lyon AR; Thavendiranathan P; Padera R; Lichtman A; Liu PP; Johnson DB; Moslehi J
    Circulation; 2019 Jul; 140(2):80-91. PubMed ID: 31390169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Awaiting a new era of cancer immunotherapy.
    Hong CW; Zeng Q
    Cancer Res; 2012 Aug; 72(15):3715-9. PubMed ID: 22815525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 0 clinical studies in oncology.
    Collins JM
    Clin Pharmacol Ther; 2009 Feb; 85(2):204-7. PubMed ID: 19109589
    [No Abstract]   [Full Text] [Related]  

  • 40. Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology.
    Orentas RJ; Mackall CL
    Crit Rev Oncog; 2015; 20(3-4):315-27. PubMed ID: 26349422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.